ctl
antigen
site
locat
residu
envelop
protein
rv
identifi
assay
employ
sp
two
e
ctl
clone
examin
immun
recognit
rv
wildtyp
attenu
vaccin
strain
recombin
protein
exact
sequenc
recogn
clone
delin
use
truncat
overlap
sp
cover
residu
defin
tcell
site
overlap
almost
complet
viru
neutral
antibodybind
site
previous
identifi
mous
monoclon
human
antibodi
seri
singl
aasubstitut
sp
analogu
use
defin
residu
critic
tcell
recognit
use
ebvbl
display
differ
hladr
haplotyp
subtyp
target
determin
mhc
class
ii
restrict
element
immun
recognit
tcell
clone
shown
associ
three
subtyp
share
common
residu
glutam
acid
posit
chain
abl
present
sp
tcell
clone
dawei
ou
lesli
ann
mitchel
margaret
ho
dian
dcari
aubrey
j
tingl
gerald
nepom
martial
lacroix
maan
zrein
abstract
ctl
antigen
site
locat
residu
envelop
protein
rv
identifi
assay
employ
sp
two
e
ctl
clone
examin
immun
recognit
rv
wildtyp
attenu
vaccin
strain
recombin
protein
exact
sequenc
recogn
clone
delin
use
truncat
overlap
sp
cover
residu
defin
tcell
site
overlap
almost
complet
viru
neutral
antibodybind
site
previous
identifi
mous
monoclon
human
antibodi
seri
singl
aasubstitut
sp
analogu
use
defin
residu
critic
tcell
recognit
use
ebvbl
display
differ
hladr
haplotyp
subtyp
target
determin
mhc
class
ii
restrict
element
immun
recognit
tcell
clone
shown
associ
three
subtyp
share
common
residu
glutam
acid
posit
chain
abl
present
sp
tcell
clone
human
immunolog
live
attenu
rv
vaccin
use
sinc
immun
infant
suscept
women
childbear
age
success
reduc
diseas
incid
nevertheless
still
medic
concern
primari
secondari
vaccin
failur
rv
vaccineassoci
arthriti
raa
raa
occur
acut
approxim
previous
seroneg
women
receiv
current
use
live
attenu
strain
rv
vaccin
affect
signific
proport
report
develop
chronic
debilit
joint
manifest
whether
due
primari
immunolog
failur
lead
rv
persist
joint
tissu
virusinduc
autoimmun
still
unresolv
henc
indic
develop
improv
secondgener
peptid
recombin
protein
modifi
infecti
viru
vaccin
employ
antigen
region
known
give
rise
protect
immun
determin
compon
new
rv
subunit
vaccin
essenti
establish
relev
antigen
site
rvspecif
effector
lymphocyt
protect
antibodi
evid
viru
studi
indic
central
role
cell
induct
specif
immun
respons
viru
antigen
ag
repres
synthet
peptid
sp
also
known
cell
recogn
foreign
ag
nativ
form
small
peptid
present
complex
major
histocompat
complex
mhc
class
ii
molecul
surfac
agpres
cell
henc
identif
relev
antigen
site
use
sp
repres
primari
sequenc
candid
vaccin
ag
character
hla
restrict
element
involv
peptid
present
cell
could
facilit
design
effect
rv
vaccin
rv
contain
three
major
antigen
envelop
glycoprotein
el
intern
capsid
protein
four
nonoverlap
domain
bind
site
rvneutral
antibodi
locat
within
residu
least
four
tcell
antigen
site
within
sequenc
also
map
use
peripher
blood
mononuclear
cell
pbmnc
tcell
line
lymphoprolifer
screen
assay
employ
rel
long
aa
sp
delin
antigen
site
recogn
b
cell
within
region
tcell
line
deriv
rvreactiv
human
donor
either
stimul
freshli
isol
pbmnc
uvinactiv
rv
strain
stimul
pbmnc
directli
sp
aa
long
span
residu
rv
e
protein
initi
studi
sever
cytotox
tlymphocyt
ctl
clone
isol
limit
dilut
specif
determin
standard
assay
use
autolog
epsteinbarr
virustransform
bcell
line
ebvbl
sensit
sp
target
two
tcell
clone
select
studi
isol
tcell
line
stimul
uvinactiv
rv
deriv
tcell
line
stimul
sp
preliminari
investig
reveal
specif
antigen
site
site
lie
within
residu
rv
protein
domain
previous
shown
target
rvneutral
antibodi
find
suggest
region
might
contain
overlap
tand
bcell
antigen
site
could
potenti
use
compon
modifi
rv
vaccin
understand
better
role
antigen
region
play
protect
immun
interact
b
cell
exact
antigen
site
recogn
clone
mhc
class
ii
restrict
element
involv
present
defin
viru
protein
rv
strain
grown
vero
cell
isol
cultur
supernat
viru
stock
titrat
immunocytochem
focu
assay
describ
previous
stock
solut
contain
focusform
unit
ffu
ml
inactiv
uv
light
nm
model
uv
product
san
gabriel
ca
usa
cm
minut
use
recombin
rv
e
protein
isol
cultur
supernat
insect
cell
line
transform
recombin
rubella
e
baculoviru
gener
provid
dr
shirley
gillam
depart
patholog
univers
british
columbia
peptid
synthesi
overlap
sp
aa
long
encompass
residu
protein
rv
strain
substitut
analogu
within
sequenc
synthes
autom
peptid
synthes
use
establish
solidphas
method
purifi
homogen
reversephas
highpressur
liquid
chromatographi
biochem
immunosystem
laval
quebec
amino
acid
analys
perform
peptid
found
good
agreement
theoret
composit
tcell
clone
use
studi
isol
two
tcell
line
deriv
singl
rvseroposit
donor
describ
previous
briefli
pbmnc
incub
uvinactiv
rv
ffuml
sp
use
final
concentr
gml
complet
medium
contain
mm
lglutamin
mm
acid
hepe
mm
penicillin
mm
streptomycin
also
supplement
autolog
plasma
day
incub
cell
wash
three
time
resuspend
cellsml
complet
rpmi
medium
supplement
fetal
calf
serum
gibco
missisauga
ontario
canada
u
human
recombin
interleukin
gibco
per
millilit
day
incub
rvor
spreactiv
lymphocyt
clone
limit
dilut
roundbottom
plate
nunc
denmark
initi
densiti
cell
per
well
presenc
uvinactiv
rv
ffuml
sp
gml
lymphoculttlf
biotest
germani
uml
irradi
rad
autolog
pbmnc
x
day
well
supplement
complet
rpmi
medium
contain
lymphoculttlf
uml
day
clone
visibl
clone
transfer
fresh
medium
distribut
three
well
flatbottom
plate
day
incub
cell
origin
clone
pool
transfer
singl
well
fourwel
plate
nunc
restimul
uvinactiv
rv
sp
presenc
irradi
autolog
pbmnc
time
ag
specif
determin
assay
use
autolog
ebvtransform
b
cell
sensit
sp
target
describ
tcell
clone
maintain
cultur
stimul
weekli
interv
cell
uvinactiv
rv
ffuml
sp
concentr
gml
presenc
autolog
irradi
pbmnc
cultur
replenish
everi
day
complet
medium
contain
concentr
describ
ebvbl
use
target
assay
ebvbl
autolog
tcell
clone
mt
aj
cm
lm
oz
establish
laboratori
donor
differ
heterozyg
hla
phenotyp
see
tabl
describ
previous
hcl
ebvbl
bsm
yar
jha
pf
kb
mat
cri
mst
sst
homozyg
hla
region
differ
hladr
phenotyp
subtyp
tabl
cellmedi
cytotox
assay
standard
assay
use
measur
ctl
respons
use
ctl
target
ebvbl
hcl
cell
sensit
overnight
incub
ffu
uvinactiv
rv
igml
gtm
sp
ml
complet
rpmi
medium
assay
employ
sp
incub
time
reduc
hour
ag
sensit
cell
wash
complet
medium
label
ci
amersham
oakvil
ontario
canada
hour
radiolabel
target
cell
wash
four
time
medium
incub
cellsat
differ
effectortarget
ratio
hour
roundbottom
plate
nunc
assay
perform
duplic
triplic
percent
specif
cytotox
calcul
formula
er
sr
mr
sr
er
experiment
releas
mean
count
per
minut
cpm
releas
supernat
presenc
cell
use
target
cell
sr
spontan
releas
mean
cpm
absenc
cell
determin
four
replic
sampl
mr
maxim
releas
mean
cpm
supernat
target
cell
incub
deterg
sigma
st
loui
mo
usa
determin
four
replic
sr
alway
mr
mab
antidr
monoclon
antibodi
mab
antidq
mab
also
provid
gtn
ascit
fluid
contain
mab
use
inhibit
ctl
respons
assay
incub
sp
sensit
target
cell
final
dilut
minut
ad
ctl
cell
polymeras
chain
reaction
pcr
sequenc
analysi
one
microgram
genom
dna
ebvbl
amplifi
pcr
use
groupspecif
primer
r
cycl
time
temperatur
cycl
pcr
product
directli
sequenc
dideoxychain
termin
method
use
taq
polymeras
oligonucleotid
primer
immun
recognit
sp
reibv
rv
strain
cytotox
tcell
clone
tcell
clone
determin
cell
flowcytometr
analysi
data
shown
clone
test
cytotox
assay
recognit
recombin
protein
wildtyp
rv
attenu
rv
vaccin
strain
clone
exhibit
strong
cytotox
autolog
ebvbl
target
sensit
sp
lesser
extent
also
kill
target
sensit
ibv
three
strain
uvinactiv
whole
rv
fig
tabl
latter
case
weakest
cytotox
observ
vaccin
strain
fig
l
elspecif
ctl
clone
identifi
exact
antigen
site
recogn
ctl
clone
also
found
elicit
lower
cytotox
natur
sequenc
fig
tabl
charg
substitut
howev
glutam
e
aspart
acid
tryptophan
w
posit
valin
v
posit
isoleucin
posit
glutamin
q
posit
substitut
nonpolar
rel
larger
residu
tyrosin
tryptophan
w
posit
posit
complet
abolish
specif
cytotox
fig
tabl
shown
ctl
hla
class
ii
restrict
element
associ
immun
recognit
antigen
site
defin
determin
mab
specif
determin
hladr
dq
respect
test
assay
abil
block
present
ofsp
e
autolog
ebvbl
spspecif
kill
mediat
clone
inhibit
preincub
spsensit
target
antihladr
mab
antihladq
mab
fig
suggest
hladr
restrict
tabl
target
cytotox
assay
result
show
antigen
site
defin
tcell
clone
recogn
context
phenotyp
autolog
ebvbl
also
share
heterolog
line
mt
tabl
homolog
line
jha
tabl
heterolog
ebvbl
express
line
aj
cm
whose
data
shown
tabl
unabl
present
tcell
clone
suggest
case
immun
recognit
like
subtyp
specif
use
hcl
ebvbl
differ
subtyp
sensit
target
cytotox
assay
determin
three
hci
sst
jha
could
present
clone
tabl
effectortarget
ratio
two
rvspecif
hladrrestrict
ctl
clone
gener
pbmnc
singl
subject
vitro
stimul
either
uvinactiv
strain
rv
sp
show
ident
antigen
specif
e
behav
cytotox
cell
phenotyp
predomin
vivo
respons
antigen
region
cell
could
function
either
immun
protect
direct
elimin
rvinfect
cell
advers
immunoreact
destruct
synovi
cell
persist
infect
rv
clone
exhibit
ident
specif
despit
gener
differ
antigen
stimuli
moreov
recogn
e
sp
also
natur
process
peptid
wildtyp
attenu
rv
vaccin
strain
well
recombin
rv
e
protein
although
three
rv
strain
consid
complet
homolog
within
residu
weaker
cytotox
observ
target
cell
hcl
express
differ
hladr
phenotyp
sensit
sp
concentr
pm
hour
ad
cell
b
autolog
ebvbl
tcell
clone
sequenc
shown
use
singlelett
code
dash
repres
ident
sequenc
residu
shown
bold
indic
uniqu
differ
subtyp
target
cell
sensit
flank
amino
acid
may
play
critic
role
recognit
given
peptid
sequenc
presum
influenc
ag
process
peptid
conform
affin
mhc
bind
sequenc
analysi
rv
structur
protein
reveal
aa
substitut
protein
rel
strain
three
substitut
report
e
henc
greater
sequenc
variabl
e
may
influenc
ag
process
delin
residu
within
e
critic
immun
recognit
ctl
clone
truncat
sp
span
region
compar
capac
target
specif
cytotox
result
show
e
shortest
sequenc
capabl
elicit
maxim
cytotox
smallest
antigen
sp
evalu
induc
somewhat
lower
level
kill
rothbard
taylor
rothbard
gefter
identifi
primari
sequenc
motif
characterist
tcell
antigen
site
consist
aa
includ
charg
residu
glycin
follow
hydrophob
aa
either
polar
residu
glycin
within
motif
evwvt
identifi
fig
assess
role
play
individu
residu
four
singl
aasubstitut
analogu
sp
e
evalu
cytotox
assay
result
show
substitut
hydrophob
residu
charg
polar
one
posit
substanti
reduc
cytotox
indic
amino
acid
import
recognit
moreov
replac
nonpolar
aa
w
posit
acid
aa
e
replac
polar
aa
rel
largers
residu
posit
obliter
specif
cytotox
henc
appear
play
critic
role
immun
recognit
sequenc
particular
ctl
clone
de
lisi
berzofski
propos
anoth
model
tcell
determin
correl
amphipath
othel
structur
antigen
protein
rv
sequenc
evwvt
also
locat
maximum
ohelix
index
within
residu
determin
shelix
potenti
hydrophil
plot
e
mab
experi
cytotox
assay
perform
differ
ebvbl
confirm
subtyp
drbi
drb
drb
could
serv
restrict
element
present
e
case
furthermor
dr
chain
autolog
ebvbl
shown
nucleic
acid
sequenc
ident
drb
molecular
divers
haplotyp
well
known
least
subtyp
express
differ
class
ii
chain
identifi
believ
critic
residu
involv
ag
present
subtyp
locat
first
domain
chain
show
variabl
abl
present
tcell
clone
differ
significantli
subtyp
posit
uniqu
substitut
e
charg
chang
could
influenc
immun
recognit
either
modifi
peptid
conform
interact
tcell
receptor
tcr
alanin
chain
report
import
tcell
alloor
autoreact
propos
hladrbind
model
consist
core
sequenc
six
amino
acid
involv
larg
hydrophob
residu
separ
four
amino
acid
small
residu
osullivan
et
al
also
propos
similar
nineresidu
motif
compos
aromat
hydrophob
aa
posit
follow
noncharg
rel
small
residu
posit
anoth
rel
hydrophob
one
posit
predict
model
data
present
herein
highli
like
respect
repres
first
second
hydrophob
anchor
residu
bind
third
allelespecif
anchor
residu
like
fig
henc
appear
critic
bind
epitop
recognit
tcell
clone
studi
fig
tabl
investig
progress
confirm
interact
critic
residu
hladrbind
groov
tcr
result
determin
influenc
residu
chain
peptid
bind
result
clonal
analysi
reveal
antigen
site
appear
highli
restrict
present
cell
may
good
incorpor
new
rv
vaccin
yet
residu
lie
within
broader
region
rv
e
appear
wide
recogn
popul
basi
cell
antibodi
individu
divers
mhc
background
would
antigen
site
locat
within
predict
immunodomin
region
exhibit
high
specif
mhc
restrict
one
possibl
explan
subtyperestrict
sequenc
identifi
repres
one
sever
cluster
antigen
site
lie
within
residu
altern
may
exist
human
tcell
repertoir
tcr
capabl
recogn
residu
context
mhc
class
ii
molecul
investig
current
way
determin
whether
case
notabl
howev
phenotyp
associ
autoimmun
diseas
system
restrict
tcr
v
gone
usag
also
interest
antigen
site
recogn
ctl
clone
describ
overlap
almost
complet
previous
defin
neutral
antibodybind
domain
ep
suggest
appar
overlap
class
ii
hlarestrict
tcell
antigen
site
antibodi
recognit
site
may
simpli
fortuit
may
reflect
mechanist
link
ag
present
tcell
help
antibodi
synthesi
overlap
band
tcell
determin
could
facilit
ag
uptak
b
cell
bear
surfac
ag
receptor
appropri
specif
follow
ag
process
present
bcell
hla
class
ii
cell
form
antigen
bridg
focu
appropri
cell
onto
b
cell
conclus
delin
tcell
antigen
site
within
rv
sequenc
overlap
almost
complet
previous
identifi
antibodybind
domain
rv
envelop
protein
suggest
region
could
function
signific
immun
protect
mediat
cell
antibodi
outcom
vivo
immun
respons
epitop
immun
protect
region
would
use
candid
develop
effect
subunit
recombin
infecti
virion
vaccin
result
studi
suggest
howev
influenc
mhc
tcr
polymorph
tcell
recognit
sp
sequenc
consid
vaccin
design
futur
studi
determin
whether
sequenc
may
recogn
human
tcr
context
mhc
class
ii
molecul
phenotyp
respond
cell
assess
suitabl
compon
secondgener
rv
vaccin
investig
also
assess
vivo
immunogen
induc
protect
nonprotect
tand
bcell
respons
